Press Releases

 

October 11, 2016 – Microbiome Therapeutics’ NM504 For Improving Blood Glucose Regulation is First Microbiome Modulator to Receive U.S. Patent Allowance

MicroBiome Therapeutics (MBT) today reported that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s patent application covering the composition and use of lead microbiome modulator NM504. The allowance includes use of NM504 in diabetic patients and prediabetics at risk of developing diabetes, and covers NM504 delivered in any format, including capsules, tablets, and food-like vehicles such as smoothies and nutrition bars.

June 6, 2015 – Microbiome Therapeutics Presents Clinical Data on Diabetes Drug NM505 at Ada’s 75th Scientific Sessions and Reports Issuance of NM505 Patent

MicroBiome TherapeuticsTM LLC, (MBT) today announced that positive clinical data on NM 505, a combination of a proprietary microbiome modulator and metformin, was presented at the 75th Scientific Sessions of the American Diabetes Association. Separately, the company announced that a U.S. patent has issued for its microbiome modulator-metformin combination, NM505.

April 7, 2015 – MicroBiome Therapeutics Reports Advances in Three Microbiome Modulator Programs as it Launches Series B Financing

MicroBiome Therapeutics LLC (MBT) announced the publication of its’ clinical study on NM505 for improvement of metformin efficacy and tolerability in Type 2 diabetics.  The Company also announced a Notice of Allowance from the U.S. Patent and Trademark Office for its’ microbiome modulator, NM504.

February 9, 2015 – MicroBiome Therapeutics Receives Notice of Allowance for U.S. Patent Covering Glyceollin as a Treatment for Diabetes and Obesity

MicroBiome Therapeutics LLC (MBT) today reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the company’s patent application covering the use of glyceollin to treat diabetes and obesity.

September 26, 2014 – Positive Proof of Concept Study Shows Microbiome Therapeutics’ NM505 May Improve Tolerability of Metformin in Type 2 Diabetes

MicroBiome Therapeutics LLC, (MBT) today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. NM505 is a combination of metformin and active ingredients contained in the company’s lead microbiome modulator, NM504.

June 23, 2014 – Data Presented at ICE/ENDO 2014 Shows MicroBiome Therapeutics’ NM504 Improves Blood Glucose Control In Diabetes and Prediabetes

MicroBiome Therapeutics LLC, (MBT) today presented positive results from a clinical trial of microbiome modulator NM504 in prediabetes and type 2 diabetes at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society.

June 16, 2014 – MicroBiome Therapeutics Cites Proof of Concept Study Showing Metformin Improves Glycemic Control In Diabetes By Shifting The Microbiome

MicroBiome TherapeuticsTM LLC, (MBT) today reported that a recently published scientific study shows that the diabetes drug, metformin, alters the bacterial populations in the gut in favor of a bacterial species that exerts specific cellular and immunological effects, resulting in improved glycemic control.

April 8, 2014 – MicroBiome Therapeutics’ Clinical Trial Data For NM504 In Type 2 Diabetes Has Been Accepted For Presentation At ICE/ENDO 2014

MicroBiome Therapeutics LLC, (MBT) today announced that data from the company’s clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.

February 18, 2014 – MicroBiome Therapeutics™ Reports Positive Top-Line Results From Clinical Trial of Microbiome Modulator NM504 in Type 2 Diabetes

MicroBiome TherapeuticsTM LLC, (MBT) today announced positive top-line results from the company’s clinical trial of lead microbiome modulator NM504 in development for type 2 diabetes and prediabetes. NM504 is designed to improve glucose tolerance and other metabolic parameters in patients with diabetes by shifting the gastrointestinal (GI) microbiome. Studies have shown that type 2 diabetics typically have GI dysbiosis, or microbial imbalances, that may contribute to the metabolic dysfunction associated with the condition.

December 16, 2013 – MicroBiome Therapeutics™ Completes Bridge Financing

MicroBiome TherapeuticsTM LLC, (MBT) today announced completion of a $1.3 million bridge financing from current investors. It is intended to support completion of the company’s two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes.

November 13, 2013 – MicroBiome Therapeutics Names Distinguished Researchers to its Clinical Advisory Board as it Advances NM504 for Diabetes Indications

MicroBiome Therapeutics LLC, (MBT) today reported that a number of distinguished clinical researchers specializing in diabetes and metabolic disorders have joined the Clinical Advisory Board (CAB) that MBT recently established to advance development of lead product NM504. MBT is developing microbiome modulators that alter bacterial populations and their environment in the gastrointestinal (GI) tract to address serious health conditions. Microbiome modulators act on multiple factors in the GI environment, providing specialized ingredients that augment the growth of targeted desirable bacterial strains and discourage the growth of others. These microbiome shifts are designed to positively affect metabolism and weight.

September 11, 2013 – Case Report Suggests MicroBiome Therapeutics’ NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control

MicroBiome Therapeutics LLC, (MBT), a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.

September 11, 2013 – NuMe Health Becomes MircoBiome Therapeutics and Recruits New CEO

NuMe Health LLC today announced that the company has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff, Ph.D., as chief executive officer.

 

NuMe Health Archive